Bristol-Myers Squibb BMY Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's enterprise value?
- Bristol-Myers Squibb (BMY) reported enterprise value of $158.92B in Q1 2026.
- How has Bristol-Myers Squibb's enterprise value changed year-over-year?
- Bristol-Myers Squibb's enterprise value decreased by 2.6% year-over-year, from $163.11B to $158.92B.
- What is the long-term trend for Bristol-Myers Squibb's enterprise value?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's enterprise value has grown at a -4.9% compound annual growth rate (CAGR), from $692.68B to $567.6B.
- What does enterprise value mean?
- What it would cost to buy the entire business, debt included and cash netted out.
- How do you interpret enterprise value?
- The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
- How does enterprise value compare across companies?
- Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.